	US 11,785,922 B2
	Recombinant vector comprising ERT2 fused to CAS9
Eun Ju Lee, Seoul (KR); and Hyo-Soo Kim, Seoul (KR)
Assigned to SEOUL NATIONAL UNIVERSITY HOSPITAL, Seoul (KR)
Appl. No. 16/624,575
Filed by SEOUL NATIONAL UNIVERSITY HOSPITAL, Seoul (KR)
PCT Filed May 3, 2018, PCT No. PCT/KR2018/005135 § 371(c)(1), (2) Date Dec. 19, 2019, PCT Pub. No. WO2018/236045, PCT Pub. Date Dec. 27, 2018.
Claims priority of application No. 10-2017-0077221 (KR), filed on Jun. 19, 2017.
Prior Publication US 2020/0128802 A1, Apr. 30, 2020
Int. Cl. C12N 15/00 (2006.01); C12N 15/113 (2010.01); C12N 15/85 (2006.01); C12N 15/09 (2006.01); A01K 67/027 (2006.01); C07K 14/72 (2006.01); C12N 9/22 (2006.01)

CPC A01K 67/0275 (2013.01) [C07K 14/72 (2013.01); C12N 9/22 (2013.01); C12N 15/113 (2013.01); C12N 15/8509 (2013.01); A01K 2217/07 (2013.01); A01K 2227/105 (2013.01); C07K 2319/09 (2013.01)]

1 Claim

1. A recombinant vector comprising: (a) a U6 promoter and a guide RNA (gRNA), and (b) a cytomegalovirus (CMV) promoter and a gene encoding a protein complex, wherein the protein complex is encoded by a gene consisting of the nucleotide sequence of SEQ ID NO: 12, and wherein the U6 promoter, the gRNA, the CMV promoter, and the gene consisting of SEQ ID No: 12 are operatively linked within the recombinant vector.